EDITORIAL

Tuberculosis and its future in the COVID-19 era: The Pulmonology series 2021

In spite of on-going continued effort and COVID-19, TB remains a major cause of preventable morbidity and mortality and public health priority.1

Pulmonology tuberculosis (TB) 2018 series was very successful and highly cited,2–10 contributing to the journal’s Impact Factor (which increased from 2.096 to 2.778, and moving it into the second quartile of Respiratory Medicine journals) (Table 1). The topics covered ranged from state-of-the-art review on new points of care diagnostic tests,7 to the new drugs pipeline,6 while discussing important clinical issues like management of TB in children11 or how to manage comorbidities and social determinant of TB.8

COVID-19 has created an unprecedented situation affecting everybody’s life (restricting social activities, travelling, attendance at school and educational activities, etc.), damaging economies (increasing poverty, lowering countries’ GDP, which are core determinants of TB) and overwhelming healthcare systems.1,11,12 Recently Global Tuberculosis Network (GTN) studies have shown the devastating impact of COVID-19 on TB Programmes and activities,12–16 and WHO has warned that previous estimates of mortality decline for TB will be reversed by COVID-19 in the absence of rapid and effective support to health programmes and TB services.1

As a contribution to the global fight against TB, Pulmonology has planned a 2021 TB series focusing on important priorities to be published in conjunction with World TB day. The choice of topics and the global perspective will be ensured by involving TB officers of the European Respiratory Society (ERS) and the Global TB Network (GTN) and contributors from experts all over the world.

We asked the GTN to report on the outcomes of their cohort of patients treated with the new TB drugs (bedaquiline and delamanid, alone or in combination). A previous global report on adverse events was published in 201917; the prospective update of the cohort (project works like an ongoing register) allows researchers to report on a variety of outcomes (sputum smear and culture conversion as well as time to bacteriological conversion) on one of the largest available datasets, to date it includes more than 850 patients from 29 countries. The global nature of the cohort involved will ensure generalizability and cross fertilisation.

A second contribution will report on a potential inter-action between TB and COVID-19, reviewing what has been published so far and covering both clinical and public health perspectives, proposing the next steps to better understand this new “cursed duet”.18

The third paper will discuss hospital admission criteria for TB patients, based on the analysis of available data (including data of duration of hospitalization from the ongoing global TB/COVID study18 and will include recommendations on the precautions required to minimise airborne transmission in healthcare settings during COVID. The document will have a consensus component to ensure a wide view, as recently performed by the GTN.15,19

It is well known that HIV co-infection, diabetes mellitus, malnutrition, tobacco use and/or alcoholism may increase the risk of progressing to TB disease. It has also been shown that settings with the highest TB incidence rates are also those with higher incidence of HIV infection, incarceration, household overcrowding, unemployment, poor working conditions and migration. New risk factors may be on the horizon, relating to a possible direct or indirect effect of the COVID-19 pandemic (e.g. poverty, fear, lockdown, difficulty accessing health services etc.). The last article of the Pulmonology TB series will be a case study on a country’s response (Portugal) within a global review of risk factors and social determinants of TB.

While calling on the scientific community, civil societies and all stakeholders involved to combine their efforts to reinforce the fight against TB, we hope the 2021 Pulmonology TB series will be useful for the cause and highlight further areas for cooperation.

https://doi.org/10.1016/j.pulmoe.2020.10.005
2531-0437 © 2020 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

15,19

2.096
Conflicts of interest
The authors have no conflicts of interest to declare.

Funding source
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Acknowledgements
The article is part of the scientific activities of the Global Tuberculosis Network (GTN) and of the WHO Collaborating Centre for Tuberculosis and Lung Diseases, Tradate, ITA-80, 2017-2020- GBM/RC/LDA.

References


G.B. Migliori✉, S. Tiberi✉, A.L. García-Basteiro✉, R. Duarte✉

✉Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti CliniciScientifici Maugeri IRCCS, Tradate, Italy

✉Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK

✉Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, UK

dISGlobal, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain

eCentro de Investigação Em Saúde de Manhiça, Maputo, Mozambique

Pulmonology Department, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal

Public Health Science and Medical Education Dept, Faculty of Medicine, University of Porto, Porto, Portugal

Corresponding author at: Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti CliniciScientifici Maugeri IRCCS, Via Roncaccio 16, Tradate, Varese, 21049, Italy.

E-mail addresses: giovannibattista.migliori@icsmaugeri.it (G.B. Migliori), s.tiberi@qmul.ac.uk (S. Tiberi), alberto.garcia-basteiro@isglobal.org (A.L. García-Basteiro), raquelafduarte@gmail.com (R. Duarte).

21 October 2020
Available online 17 November 2020